Clinical Report: Correction on Nurr1 Deficiency and Liver-Gut Pathology

Background

Nurr1 (NR4A2) is a nuclear receptor that regulates inflammatory homeostasis. Its systemic role in organ communication remains underexplored. This correction emphasizes the importance of accurate authorship in disseminating research findings.

Data Highlights

No numerical or trial data is presented in the correction article.

Key Findings

• Correction of author affiliations for multiple contributors to the study.
• Removal of erroneous affiliations for authors Muhammad Adeel Ejaz, Sajjad Ali Shah, Yin-Xiong Li, and Shah Faisal.
• Clarification of the affiliation list to ensure accurate representation of authors' institutions.
• Emphasis on the importance of accurate author attribution in scientific publications.

Clinical Implications

This correction serves as a reminder for the importance of verifying authorship in scientific publications.

Conclusion

This correction addresses errors in author affiliations.

Related Resources & Content

1. Faisal S, Ullah I, Kambey PA, Malik A, Ejaz MA, Shah SA, Li Y-X, Frontiers in Immunology, 2026 -- Correction: Nurr1 Deficiency Drives a Liver-Gut Pathological Connection Identified Through Multi-Omics and Advanced Histopathological Analysis
2. npj Digital Medicine — Combining Multi-Omics Approaches with Machine Learning to Unravel Cellular Diversity and Fibrotic Regulatory Pathways in the Transition from MASLD to MASH
3. Infection — Investigating Gut Barrier Dysfunction's Impact on Postoperative Outcomes Following Liver Transplantation: Insights into Pathophysiology and Treatment Options
4. Journal of Gastroenterology — Inhibition of C5aR1 Reduces Liver Inflammation and Fibrosis in a NASH Mouse Model Through Modulation of TLR4 Pathway and Macrophage Polarization
5. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) - Journal of Hepatology
6. Introducing AGA’s new MASLD clinical care pathway – American Gastroenterological Association
7. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance - PubMed
8. A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis - PubMed
9. Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis | New England Journal of Medicine
10. Consensus position statements for the standardized application of histological grading and staging systems in MASH clinical trials - Journal of Hepatology
11. FDA Qualifies First AI Drug Development Tool, Will Be Used in 'MASH' Clinical Trials | FDA
12. Recommendations for Performance Evaluation of Machine Learning in Pathology: A Concept Paper From the College of American Pathologists - PubMed